Dr. David Reynoso, MD, PhD

Dr. Reynoso practices at John Sealy Hospital in Galveston, Texas, part of The University of Texas System.

Dr. Reynoso's NPI, 1205198405, was assigned on June 13, 2012. Dr. Reynoso graduated from McGovern Medical School in 2012. Dr. Reynoso holds Texas license Q3584.

Dr. Reynoso's primary practice is John Sealy Hospital, at 301 University Boulevard, Galveston, TX 77555 in Galveston County. The practice phone is (409) 772-1011.

Dr. Reynoso's primary practice is John Sealy Hospital in Galveston, Texas, part of The University of Texas System. The medical group on file is UTMB Faculty Group Practice. Dmand AI also links Dr. Reynoso to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reynoso practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Reynoso's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Reynoso is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Reynoso's licenses on file in 2 states: Texas and Indiana.

Dmand AI lists hiv/aids, joint or bone infection and pneumonia among the conditions Dr. Reynoso treats.

CMS data shows 207 Medicare services from Dr. Reynoso across 5 procedure codes in 2024, for 111 Medicare patients. Medicare paid $16,143 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 111 Medicare patients who saw Dr. Reynoso in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 27% are also on Medicaid. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reynoso's median patient age at 68, with 41% women.

In 2024, Dr. Reynoso wrote 185 Medicare Part D claims for 30 patients. 49% of them were for generic drugs. CMS names the drug for 94 of them, across 4 drugs with 11 or more claims each, at $232,969 in total drug cost. In 2023, CMS named 126 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Reynoso for performance year 2024, reported as part of a group. Dr. Reynoso accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 41 papers to Dr. Reynoso, published from 2006 to 2024. 2021 was the busiest year, with 9. The most frequent topics are Cell Line, Tumor, Anti-Bacterial Agents and COVID-19. Dr. Reynoso has published most often in Clin Cancer Res. Dr. Reynoso's most frequent co-authors are Jonathan C. Trent, MD, PhD, Khaled Fouad Chatila, MD and Anthony Paul Conley, MD.

CMS Open Payments shows 14 general payments to Dr. Reynoso from 5 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 79% of the total. Insmed, Inc. paid the most, $6,774.

Dmand AI lists 4 awards for Dr. Reynoso, most recently Alpha Omega Alpha member in 2022.

Dr. Reynoso graduated from McGovern Medical School in 2012. Dr. Reynoso is a member of Idsa.

Dr. Reynoso is in network with 22 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 14. Check the plan with the practice before a visit.